What’s new in the toolbox for constipation and fecal incontinence?

Yeong Yeh Lee¹,²*

¹ School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, Malaysia
² Section of Gastroenterology and Hepatology, Department of Medicine, Medical College of Georgia, Georgia Regents University, Augusta, GA, USA

INTRODUCTION

Both constipation and fecal incontinence (FI) are common complaints predominantly affecting the elderly and women. They are associated with significant morbidity and high healthcare costs. The causes are often multi-factorial and overlapping. With the advent of new technologies, we have a better understanding of their underlying pathophysiology which may involve disruption at any levels along the gut–brain–microbiota axis. Initial approach to management should always be the exclusion of secondary causes. Mild symptoms can be approached with conservative measures that may include dietary modifications, exercise, and medications. New prokinetics (e.g., prucalopride) and secretagogues (e.g., lubiprostone and linaclotide) are effective and safe in constipation. Biofeedback is the treatment of choice for dyssynergic defection. Refractory constipation may respond to neuromodulation therapy with colectomy as the last resort especially for slow-transit constipation of neuropathic origin. Likewise, in refractory FI, less invasive approach can be tried first before progressing to more invasive surgical approach. Injectable bulking agents, sacral nerve stimulation, and SECCA procedure have modest efficacy but safe and less invasive. Surgery has equivocal efficacy but there are promising new techniques including dynamic graciloplasty, artificial bowel sphincter, and magnetic anal sphincter. Despite being challenging, there are no short of alternatives in our toolbox for the management of constipation and FI.

Constipation and fecal incontinence (FI) are common complaints predominantly affecting the elderly and women. They are associated with significant morbidity and high healthcare costs. The causes are often multi-factorial and overlapping. With the advent of new technologies, we have a better understanding of their underlying pathophysiology which may involve disruption at any levels along the gut–brain–microbiota axis. Initial approach to management should always be the exclusion of secondary causes. Mild symptoms can be approached with conservative measures that may include dietary modifications, exercise, and medications. New prokinetics (e.g., prucalopride) and secretagogues (e.g., lubiprostone and linaclotide) are effective and safe in constipation. Biofeedback is the treatment of choice for dyssynergic defection. Refractory constipation may respond to neuromodulation therapy with colectomy as the last resort especially for slow-transit constipation of neuropathic origin. Likewise, in refractory FI, less invasive approach can be tried first before progressing to more invasive surgical approach. Injectable bulking agents, sacral nerve stimulation, and SECCA procedure have modest efficacy but safe and less invasive. Surgery has equivocal efficacy but there are promising new techniques including dynamic graciloplasty, artificial bowel sphincter, and magnetic anal sphincter. Despite being challenging, there are no short of alternatives in our toolbox for the management of constipation and FI.

Keywords: constipation, fecal incontinence, anorectal disorders, pathophysiology, management

CONSTIPATION PATHOPHYSIOLOGY

The colon serves as a conduit for transporting formed stools into the anorectum for evacuation when socially acceptable. The functions are coordinated through neurotransmitters (acetylcholine, nitric oxide, serotonin, calcitonin gene-related peptide), colonic reflexes, learned behaviors, and gut microbiota. These functions can be disrupted at any levels along the gut–brain–microbiota axis. Neuropathy or myopathy can result in slow-transit constipation (Figure 1), which may be localized or is part of a more generalized form of dysmotility and pseudo-obstruction syndrome. With colonic manometry, the phasic motor activity may exhibit significant impairment in response to a meal (13) and upon waking in the morning. The periodic rectal motor activity (PRMA) may be increased (14) and this will retard colonic propulsion. There is some evidence for hormonal involvement which may explain the female predominance (15). Of interest, methanogenic flora has been found to be significantly associated with constipation (16, 17) and its elimination with antibiotics has been shown to improve symptoms (18).

www.frontiersin.org
On the other hand, DD is often an acquired form of behavioral disorder in adulthood and a third arises during childhood (19). The paradoxical anal contraction during bearing down is a result of poor rectoanal muscles coordination (Figure 2). Rectal hyposensitivity and abnormal rectal compliance are frequently associated with DD (20) and their improvement with biofeedback suggests they are consequences rather than causative (21). More recently, puborectalis muscle has been shown to play an important role in preserving fecal continence (22) and also in sensorimotor response that coincides with the desire to defecate (23).

The pathophysiology of IBS-C is more complex and data suggest it is almost indistinguishable from FC since abdominal pain is not exclusive to IBS-C alone. Abnormal colonic transit (24), visceral hypersensitivity (25), psychological factors including stress,
anxiety, and depression (26), and small intestinal bacterial overgrowth (SIBO) (27) have all been implicated with IBS-C but recent evidence indicates that serotonin dysregulation is probably the key. Both FC and IBS-C exhibit elevated levels of 5-hydroxytryptamine (5-HT) in the mucosa and reduced concentrations of platelet-depleted plasma (PDP) 5-HT after meals (28, 29). It has been shown by Shekhar et al. that patients with IBS-C tend to be at the sensitive end and FC at the insensitive end of the visceral sensitivity following meal (30).

GENERAL MANAGEMENT OF CONSTIPATION
Underlying secondary causes of constipation should be evaluated and treated first. Besides endoscopy and blood tests, exclusion of organic disorders may require specialized tests that include high-resolution or high-definition anorectal manometry, 3D-endoanal ultrasound, pelvic MRI, colonic manometry, and electrophysiological tests. Drugs that may cause constipation should be looked for and stopped. Generous amount of fluids (between 1.5 and 2.0 L/day), fiber intake (25 g/day), and exercise to improve gut transit are general advice commonly given to patients but evidence are lacking (31, 32) (Table 1). Laxatives are frequently prescribed by physicians and many patients can buy them over-the-counter. Examples of laxatives include bulking agents (e.g., psyllium), stool softeners (e.g., docusate), stimulants (e.g., senna), osmotic laxatives (e.g., polyethylene glycol), and enemas (e.g., phosphate). There are no firm recommendations on the use of laxatives in most guidelines largely due to their lack of efficacy and safety concerns (33) (Table 1). Polyethylene glycol is perhaps the exception having good data on its efficacy and safety (33).

NEW DRUGS IN THE TOOLBOX FOR THE MANAGEMENT OF CONSTIPATION
Prokinetics (e.g., prucalopride) and secretagogues (e.g., lubiprostone, linaclotide) are new agents that can restore colonic function in constipation (Table 1). Prokinetics are 5-HT4 agonists that accelerate colonic transit time and also gastric emptying time. An earlier version of 5-HT4 agonist, tegaserod, was shown to be effective in clinical trials (34), but the drug had been withdrawn from the market due to its coronary and cerebrovascular side effects. Safer drugs including mosapride (35) and renzapride (36) are in the pipeline but highly selective 5-HT4 agonist, prucalopride, has been shown in clinical trials to be effective and with little adverse events (37). Available as 2 or 4 mg qd, prucalopride is approved for use in Europe and Asia but not in the US. Velusetrag and naronapride are other high selective 5-HT4 agonists (37).

By promoting intestinal secretion, secretagogues produce softer stools but also accelerate intestinal transit. Lubiprostone acts on the type 2 chloride channels (CIC-2) that leads to active secretion of chloride into the luminal tract and it has been shown to improve small bowel and colonic transit time, however, gastric emptying appears to be delayed (38, 39). Given as 24µg bid for 3 weeks, lubiprostone (Amizita®; Sucampo Pharmaceuticals, Bethesda, MA, USA) has been shown in a number of randomized controlled trials (RCTs) to be effective in improving bowel movement, stool consistency, and also reduced bloating (33, 40). Linaclotide, another secretagogue, has a different mechanism of action where it acts on the guanylate cyclase-C (GC-C) that leads to a rise in the cyclic guanosine monophosphate and subsequently chloride and bicarbonate secretion into the lumen (41, 42). Similarly, a number of RCTs have proven the efficacy and safety...
Table 1 | Evidence-based management of constipation.

| Treatment modalities          | Prescription | Level of evidence |
|-------------------------------|--------------|-------------------|
| Fluids                        | 1.5–2.0 L/day | Level III, grade C |
| Dietary fiber                 | 25 g/day     | Level II, grade B  |
| Psyllium (e.g., Metamucil)    | 5.1 g bid/day | Level II, grade B  |
| Methylcellulose (e.g., Citrucel) | 1.5–3 g bid/day | Level III, grade C |
| Lactulose (e.g., Duphalac, Enulose) | 10–20 g/15–30 mL/day | Level II, grade B |
| Polyethylene glycol (e.g., Mirilax) | 17 g in 4–8 oz water/day | Level I, grade A |
| Senna (e.g., Senokot)         | 15–25 mg/day | Level III, grade C |
| Bisacodyl (e.g., Dulcolax)    | 5–15 mg/day  | Level III, grade C |
| Prucalopride (e.g., Resolor)  | 2–4 mg qd/day | Level I, grade A  |
| Lubiprostone (e.g., Amitiza)  | 24 µg bid/day | Level I, grade A  |
| Linaclootide (e.g., Linzess)  | 145–290 µg qd/day | Level I, grade A |
| Antibiotics (e.g., neomycin)  | 500 mg bid for 10 days | Level II, grade B |
| Probiotics                    | Strain-specific Level II, grade A (IBS) Level III, grade C (FC) |
| Biofeedback therapy           | Six 2-weekly sessions | Level I, grade A |
| Surgery                       | Colostomy ± ileostomy or ileorectal anastomosis | Level II, grade B |
| Neurmodulation therapy        | Temporary followed by permanent implant of sacral nerve stimulator | Level II, grade B |

Level I: good evidence-consistent results from well-designed, well-conducted trials. Level II: fair evidence-results show benefit, but strength is limited by the number, quality, or consistency of the individual studies. Level III: poor evidence-insufficient because of limited number or power of studies, and flaws in their design or conduct. Grade A: good evidence in support of the use of a treatment modality. Grade B: moderate evidence in support of the use of a treatment modality. Grade C: poor evidence to support a recommendation for or against the use of the modality. Grade D: moderate evidence against the use of the modality, and Grade E: good evidence to support a recommendation against the use of the modality. IBS, irritable bowel syndrome; FC, functional constipation.

of linaclotide (Linzess®; Ironwood Pharmaceuticals, Cambridge, MA, USA) given as 145 or 290 µg qd for 12 weeks (43). Linaclotide is currently approved in the US and Europe but lubiprostone is only approved in the US.

**MANAGEMENT OF DIFFICULT AND REFRACTORY CONSTIPATION**

Biofeedback is the treatment of choice for DD as shown in clinical trials (44, 45) (Table 1). It involves neuromuscular conditioning to improve rectoanal coordination and sensory training to improve stool awareness and rectal compliance. On average, four to six sessions are needed with an interval of 2 weeks, with each session lasting approximately an hour (46). With completion of training, periodic reinforcements are needed to sustain its efficacy over long-term. A trained and experienced staff and highly motivated patient are crucial to the success for this form of therapy. If present, SIBO especially methane-producing bacteria should be treated with antibiotics (18, 47). There may be a role for probiotics as part of the treatment paradigm especially in IBS (48, 49). There is also evidence that intestinal transit time in constipated patients can be reduced with probiotics (50). The benefits for probiotics are at most modest and many experts agree that probiotics do not have a firm recommendation in the management of constipation as yet (51, 52).

Patients with slow-transit constipation due to an underlying neuropathy are often refractory to any form of medical therapy and surgery should be considered in such case (53, 54). Colectomy and ileostomy or ileorectal anastomosis is usually required except in certain cases of segmental involvement especially among children (55, 56). Surgery will not improve abdominal pain or dyssynergia and may develop diarrhea and or FI following the operation (57). In selected patients, neurmodulation therapy or sacral nerve stimulation (SNS) has emerged as an alternative to surgery (Table 1). It requires a temporary placement of percutaneous lead to assess for any treatment response before permanent implantation. A recent meta-analysis has shown that initial evaluation was successful in 42–100% of patients with constipation and in those who had permanent SNS, 87% of patients achieved successful improvement in symptoms, quality of life, and satisfaction scores (58). Mechanisms underlying the success of SNS are still unclear.

**FECAL INCONTINENCE**

**PATHOPHYSIOLOGY**

Fecal incontinence is a multi-factorial disorder and some of the risk factors have included obstetric trauma (59, 60), anal trauma or surgery (61), pelvic radiotherapy for cancer (62), smoking (60, 63), obesity (63), diabetes (64), and also certain neurological conditions (65). The greater prevalence among females is attributed to maternal injuries sustained during childbirth and in late-onset FI, is due to changes in the pelvic floor from menopause, aging, and pudendal neuropathy (11, 66). Moreover, aging females tend to have lower anal resting pressure and shorter balloon expulsion time (22) (Figure 2). Hormones can also influence the strength and vigor of pelvic muscles (67, 68).

Besides external and internal anal sphincters, puborectalis also plays an important role in the control of continence (69) and injuries to these muscles and the supplying nerves, often in combinations, will result in FI. Unrecognized progressive neuropathy may explain why most women who sustained an obstetrical trauma in their 20s or 30s present with FI only in their 50s. Several studies have shown that neuropathic injury is a recognized cause for FI (70–72) and this is especially so among women with sphincter defects (73). There has been little progress in techniques to investigate for possible neuropathy other than needle electromyography (EMG) and pudendal nerve terminal latency (PNTL) introduced...
three decades ago. Both have significant limitations that prevent widespread clinical use (74). Most importantly, the involvement of spino-rectal and spino-anal pathway cannot be evaluated in a comprehensive manner with either EMG or PNTL. Recently, the availability of magnetic stimulation of the peripheral spinal roots may change this paradigm (65, 75).

Rectal compliance and sensation may also affect continence (Figure 2). A loss of rectal compliance will allow small volume of stool to generate high intra-rectal pressure and thereby overwhelm the anorectal sensation (76). This is made worse if the anorectal sensation is also impaired leading to excessive accumulation of stool (77). DD may also allow fecal seepage (78) especially in the elderly or children with fecal impaction.

GENERAL MANAGEMENT OF FI
As with approach to constipation, secondary causes of FI should be evaluated and treated. Those with mild symptoms may respond to dietary modifications, medications, and exercises. Avoidance of food triggers including caffeine, citrus fruits, spicy foods, alcohol, or dairy products in those with intolerance may help but evidence is lacking (7) (Table 2). Opinions also differ with regards to the role of dietary fiber even though there is some suggestions that methylcellulose may be better tolerated (79). Antidiarrheal agents including loperamide and diphenoxylate can provide short-term relief (80). Drugs that can enhance the sphincter tone, for example phenylephrine and sodium valproate may be useful in the passive form of FI (80). More recently, clonidine, an alpha-2 agonist, was shown to improve FI in a pilot study (63) but subsequent RCT failed to show any benefits (81).

PELVIC FLOOR EXERCISE, BIOFEEDBACK, AND TRANSCUTANEOUS ELECTRICAL STIMULATION THERAPY
Pelvic floor muscle training or anal sphincter exercise can re-train the striated muscles, i.e., external anal sphincter and puborectalis but there is no consensus on the best regimen. It can be a single regimen for all patients, e.g., 10 squeezes of 5 s each 5 times/day or it can be individualized. Exercise can also be combined with biofeedback therapy which has been shown to be twice as effective as exercise alone in a study (82) (Table 2). There are considerable variations in protocols across different centers but to be successful, emphasis is the same, i.e., education, practice, motivation, and good patient-therapist interaction. Long-term follow-up at 12 months suggests a continued response and a lower fecal incontinence severity index (FISI) scores among the biofeedback-treated patients (83). Transcutaneous electrical stimulation, either alone or in combination with biofeedback, has been shown to be useful (82) but the numbers are relatively small and further studies are needed.

MINIMAL OR LESS INVASIVE TREATMENTS
In those FI patients previously failing conservative therapy, surgery is the last option until recently when minimal or less invasive treatments are available. These include injectable bulking agents, neuremodulation therapy in the form of permanent implant of sacral nerve stimulator, and radiofrequency anal sphincter remodeling (SECCA procedure) (Table 2; Figure 3).

Biofeedback therapy which has been shown to be twice as effective as exercise alone in a study (82) (Table 2). There are considerable variations in protocols across different centers but to be successful, emphasis is the same, i.e., education, practice, motivation, and good patient-therapist interaction. Long-term follow-up at 12 months suggests a continued response and a lower fecal incontinence severity index (FISI) scores among the biofeedback-treated patients (83). Transcutaneous electrical stimulation, either alone or in combination with biofeedback, has been shown to be useful (82) but the numbers are relatively small and further studies are needed.

MINIMAL OR LESS INVASIVE TREATMENTS
In those FI patients previously failing conservative therapy, surgery is the last option until recently when minimal or less invasive treatments are available. These include injectable bulking agents, neuromodulation therapy in the form of permanent implant of sacral nerve stimulator, and radiofrequency anal sphincter remodeling (SECCA procedure) (Table 2; Figure 3).

Biofeedback therapy which has been shown to be twice as effective as exercise alone in a study (82) (Table 2). There are considerable variations in protocols across different centers but to be successful, emphasis is the same, i.e., education, practice, motivation, and good patient-therapist interaction. Long-term follow-up at 12 months suggests a continued response and a lower fecal incontinence severity index (FISI) scores among the biofeedback-treated patients (83). Transcutaneous electrical stimulation, either alone or in combination with biofeedback, has been shown to be useful (82) but the numbers are relatively small and further studies are needed.

MINIMAL OR LESS INVASIVE TREATMENTS
In those FI patients previously failing conservative therapy, surgery is the last option until recently when minimal or less invasive treatments are available. These include injectable bulking agents, neuromodulation therapy in the form of permanent implant of sacral nerve stimulator, and radiofrequency anal sphincter remodeling (SECCA procedure) (Table 2; Figure 3).

Biofeedback therapy which has been shown to be twice as effective as exercise alone in a study (82) (Table 2). There are considerable variations in protocols across different centers but to be successful, emphasis is the same, i.e., education, practice, motivation, and good patient-therapist interaction. Long-term follow-up at 12 months suggests a continued response and a lower fecal incontinence severity index (FISI) scores among the biofeedback-treated patients (83). Transcutaneous electrical stimulation, either alone or in combination with biofeedback, has been shown to be useful (82) but the numbers are relatively small and further studies are needed.

MINIMAL OR LESS INVASIVE TREATMENTS
In those FI patients previously failing conservative therapy, surgery is the last option until recently when minimal or less invasive treatments are available. These include injectable bulking agents, neuromodulation therapy in the form of permanent implant of sacral nerve stimulator, and radiofrequency anal sphincter remodeling (SECCA procedure) (Table 2; Figure 3).

Biofeedback therapy which has been shown to be twice as effective as exercise alone in a study (82) (Table 2). There are considerable variations in protocols across different centers but to be successful, emphasis is the same, i.e., education, practice, motivation, and good patient-therapist interaction. Long-term follow-up at 12 months suggests a continued response and a lower fecal incontinence severity index (FISI) scores among the biofeedback-treated patients (83). Transcutaneous electrical stimulation, either alone or in combination with biofeedback, has been shown to be useful (82) but the numbers are relatively small and further studies are needed.

MINIMAL OR LESS INVASIVE TREATMENTS
In those FI patients previously failing conservative therapy, surgery is the last option until recently when minimal or less invasive treatments are available. These include injectable bulking agents, neuromodulation therapy in the form of permanent implant of sacral nerve stimulator, and radiofrequency anal sphincter remodeling (SECCA procedure) (Table 2; Figure 3).

Biofeedback therapy which has been shown to be twice as effective as exercise alone in a study (82) (Table 2). There are considerable variations in protocols across different centers but to be successful, emphasis is the same, i.e., education, practice, motivation, and good patient-therapist interaction. Long-term follow-up at 12 months suggests a continued response and a lower fecal incontinence severity index (FISI) scores among the biofeedback-treated patients (83). Transcutaneous electrical stimulation, either alone or in combination with biofeedback, has been shown to be useful (82) but the numbers are relatively small and further studies are needed.

MINIMAL OR LESS INVASIVE TREATMENTS
In those FI patients previously failing conservative therapy, surgery is the last option until recently when minimal or less invasive treatments are available. These include injectable bulking agents, neuromodulation therapy in the form of permanent implant of sacral nerve stimulator, and radiofrequency anal sphincter remodeling (SECCA procedure) (Table 2; Figure 3).

Biofeedback therapy which has been shown to be twice as effective as exercise alone in a study (82) (Table 2). There are considerable variations in protocols across different centers but to be successful, emphasis is the same, i.e., education, practice, motivation, and good patient-therapist interaction. Long-term follow-up at 12 months suggests a continued response and a lower fecal incontinence severity index (FISI) scores among the biofeedback-treated patients (83). Transcutaneous electrical stimulation, either alone or in combination with biofeedback, has been shown to be useful (82) but the numbers are relatively small and further studies are needed.
been reported to be efficacious, safe, and durable with significant improvement in incontinence scores and quality of life scores (86). The pre-filled NASHA-Dx injection (for example, Solesta®; Salix Pharmaceuticals, Raleigh, USA) at four quadrants 5 mm above the dentate line with 1 mL each can be given as outpatient without anesthesia. A single re-treatment can be offered to patients having persistent FI after a month.

In 1995, Matzel et al. first reported the successful use of SNS in patients with FI and without sphincter defects (87). In a recent meta-analysis, it was shown that SNS, compared to conservative management, significantly improved the weekly incontinence episodes with minimal complication rates of 15% (88). A successful outcome of therapy is typically reported as 50% reduction of incontinence episodes from baseline. Besides being effective, short-term and longer term outcome at 5 years for SNS have been reported to be 42.6% based on intention-to-treat analysis (89). Sphincter defects does not contradict the placement of SNS despite initial concerns although complicated pelvic floor disorders (including rectal resections, pelvic radiotherapy, spinal lesions, double incontinence, and anal sphincter atrophy) are less likely to respond. The mechanisms that underlie the success of SNS are not entirely clear but may involve improvement in sphincter pressure (88), rectal sensitivity (90), modulation of colonic motility (91), or alterations in corticoanal excitability (92, 93).

The SECCA procedure (Mederi Therapeutics Inc., Norwalk, USA) delivers temperature-controlled radiofrequency energy to the anorectal junction resulting in tissue damage, remodeling, scarring, and contraction in order to narrow the anal canal (94). So far, data on its efficacy have been variable and at best modest since most patients continued to have moderate FI (95, 96).

SURGERY AND OTHER INVASIVE PROCEDURES
This is the last resort after failure of conservative and less invasive approach but recent systematic review appears to be inconclusive on the efficacy of surgical options in FI. If all else fails, colostomy is considered to be the very final option. Some of the surgical techniques described in literatures have included anal sphincteroplasty, graciloplasty, artificial bowel sphincter, and magnetic anal sphincter devices (Table 2; Figure 3). Of these, anal sphincteroplasty, which repairs or creates a new functional sphincter fashioned from adjacent skeletal muscles, has disappointing results in clinical studies including long-term outcome (97–100). Graciloplasty utilizes the gracilis muscle to form a new sphincter and may have an electrical stimulator implanted in the abdominal wall (dynamic graciloplasty) to maintain the sphincter tone (101). The success has been variable and only a few reports are available (102–104). Artificial bowel sphincter is an inflatable cuff that acts as a sphincter and it can be deflated when the patient desires to defecate. Again, the success has been variable from reported studies and it is associated with high complication rates that eventually require removal of the device (105–107). Magnetic anal sphincter involves placement of interlinked titanium beads having internal magnetic
cores that encircles the external anal sphincter (108). To date, the efficacy data of this procedure appear promising (109–111) but more studies are needed before it will see wider clinical use.

CONCLUSION
Both constipation and FI are common gastrointestinal complaints having multi-factorial origins. Commonly affecting elderly and women, these disorders are associated with significant impairment in quality of life and high healthcare costs. Availability of new technologies and molecular techniques allow a better understanding of their underlying physiopathology that may involve any levels along the gut–brain–microbiota axis. Many patients with mild symptoms of constipation and FI may respond to conservative approach that consists of diet modifications, exercise, biofeedback therapy, and medications. More refractory cases of constipation would require neuromodulation therapy and surgery. Likewise, in refractory FI, less invasive approach can be tried first including injectable bulking agents, SNS, and SECCA before moving on to more invasive surgical approach that includes graciloplasty, artificial bowel sphincter, or magnetic anal sphincter.

REFERENCES
1. Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol (2011) 106:1582–91. doi:10.1038/ajg.2011.164
2. Leung FW, Rao SSC. Fecal incontinence in the elderly. Gastroenterol Clin North Am (2009) 38:503–11. doi:10.1016/j.gtc.2009.06.007
3. Dunivan GC, Heymen S, Palsson OS, von Korff M, Turner MJ, Melville JL, et al. Fecal incontinence in primary care: prevalence, diagnosis, and health care utilization. Am J Obset Gynecol (2010) 202:e1–6. doi:10.1016/j.ajog.2010.01.018
4. Nellesen D, Yee K, Chawla A, Lewis BE, Carson RT. A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation. J Manag Care Pharm (2013) 19:755–64.
5. Bharucha AE, Wald A, Enck P, Rao S. Functional anorectal disorders. Gastroenterology (2006) 130:1510–8. doi:10.1053/j.gastro.2005.11.064
6. Whitehead WE, Wald A, Diamant NE, Enck P, Pemberton JH, Rao SS. Functional disorders of the anus and rectum. Gut (1999) 45(Suppl 2):II55–9. doi:10.1136/gut.45.2008.iii5
7. Rao SSC. Diagnosis and management of fecal incontinence. American college of gastroenterology practice parameters committee. Am J Gastroenterol (2004) 99:1585–604. doi:10.1111/j.1572-0241.2004.00105.x
8. Stewart WE, Liberman IN, Sandler RS, Woods MS, Stemhagen A, Chee E, et al. Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features. Am J Gastroenterol (1999) 94:5350–40. doi:10.1111.j.1572-0241.1999.01642.x
9. van den Berg MM, Bennenga MA, Di Lorenzo C. Epidemiology of childhood constipation: a systematic review. Am J Gastroenterol (2006) 101:2401–9. doi:10.1111/j.1572-0241.2006.00771.x
10. van Ginkel R, Reitsma JB, Buller HA, van Wijk MP, Taminiau JAM, Bennenga MA. Childhood constipation: longitudinal follow-up beyond puberty. Gastroenterology (2003) 125:357–63. doi:10.1053/s0016-5085(03)00888-6
11. Whitehead WE, Borrador L, Goode PS, Meikle S, Mueller EB, Tuteja A, et al. Fecal incontinence in US adults: epidemiology and risk factors. Gastroenterology (2009) 137:512–7. doi:10.1053/j.gastro.2009.04.054
12. Leung FW, Schnelle JF. Urinary and fecal incontinence in nursing home residents. Gastroenterol Clin North Am (2008) 37:697–707. doi:10.1016/j.gtc.2008.06.005
13. Rao SSC, Orszark B, Stessman M. Investigation of the pathophysiology of fecal seepage. Am J Gastroenterol (2004) 99:2284–9. doi:10.1111/j.1572-0241.2004.04037.x
14. Rao SS, Sadeghi P, Batterson K, Beaty J. Altered periodic rectal motor activity: a mechanism for slow transit constipation. Neurogastroenterol Motil (2001) 13:591–8. doi:10.1046/j.1365-2982.2001.00292.x
15. Preston DM, Lennard-Jones JE. Severe chronic constipation of young women: “idioopathic slow transit constipation”. Gut (1986) 27:41–8. doi:10.1136/gut.27.1.41
Bryant AP, Busby RW, Bartolini WP, Cordero EA, Hannig G, Kessler MM, et al.
Camilleri M, Bharucha AE, Ueno R, Burton D, Thomforde GM, Baxter K, et al.
Lembo AJ, Johanson JF, Parkman HP, Rao SS, Miner PB, Ueno R. Long-term
Chan WW, Mashimo H. Lubiprostone increases small intestinal smooth muscle
Rao SSC, Valestin J, Brown CK, Zimmerman B, Schulze K. Long-term efficacy
Quigley EMM. Probiotics in the management of functional bowel disorders:
Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ,
Miller LE, Ouwehand AC. Probiotic supplementation decreases intestinal tran-
Korterink JJ, Ockeloen L, Benninga MA, Tabbers MM, Hilbink M, Deckers-
Lubiprostone is a potent and selective guanylate cyclase C agonist that elicits phar-
Linaclotide is a potent and selective guanylate cyclase C agonist that elicits phar-
Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal
Shin A, Camilleri M, Kolar G, Erwin P, West CP, Murald MH. Systematic review
Scarpellini E, Tack J. Norepinephrine: a new drug for the treatment of constipation in
Shen W, Mashimo H. Lubiprostone increases small intestinal smooth muscle contractions through a prostaglandin E receptor 1 (EP1)-mediated pathway.
J Neurogastroenterol Motil (2013) 19:312–8. doi:10.5053/jnm.2013.9.3.312
Camilleri M, Bharucha AE, Ueno R, Burton D, Thomforde GM, Baxter K, et al.
Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointestinal Liver Physiol (2006) 290:C942–7. doi:10.1152/ajpgi.00264.2005
Leno AE, Johnson JF, Parkman HP, Rao SS, Miner PB, Ueno R. Long-term safety and effectiveness of lubiprostone, a chloride channel (CIC-2) activator, in patients with chronic idiopathic constipation. Dig Dis Sci (2011) 56:2639–45. doi:10.1007/s10620-011-1801-0
Andreasen V, Camilleri M, Busciglio IA, Grudell A, Burton D, McKinzie S, et al.
Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gut (2010) 59:870–6. doi:10.1136/gut.2010.03.015
Videcolol EI, Cheng V, Cremonini F. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis. Clin Gastroenterol Hepatol (2011) 13:1084.e9–2.e13. doi:10.cggh.2010.08.044
Rao SSC, Seide BM, Zinsmeister AR. The effects of clonidine on symptoms and anorectal sensorimotor function in women with fecal incontinence. Aliment Pharmacol Ther (2010) 32:681–8. doi:10.1111/j.1365-2036.2010.04391.x
Rey E, Choung RS, Schleck CD, Zinsmeister AR, Locke GR, Talley NJ. Onset and risk factors for fecal incontinence in a US community. Am J Gastroenterol (2010) 105:612–9. doi:10.1111/j.1572-0241.2009.03984.x
Tantiphaschika K, Attaluri A, Valentin J, Yamada T, Rao SSC. Transluminal and transsacral motor-evoked potentials: a novel test for spino-anorectal neuropathy in spinal cord injury. Am J Gastroenterol (2011) 106:907–14. doi:10.1038/ajg.2010.478
Bohle B, Belvis F, Vial M, Maestre Y, Pera M, Castillo M, et al. Menopause and obstetric history as risk factors for fecal incontinence in women. Dis Colon Rectum (2011) 54:975–81. doi:10.1097/DCR.0b013e31821404a
Haadem K, Ling L, Ferno M, Graffner H. Estrogen receptors in the external anal sphincter. Am J Obstet Gynecol (1991) 164:609–10. doi:10.1016/S0002-9378(11)80032-3
Knaudsen UB, Laurberg S, Danielsen CC. Age-related changes in the striated anal sphincter in female rats. A quantitative morphometric study. Scand J Gastroenterol (1991) 26:347–52. doi:10.3109/03009529010902553
Parks AG. Royal society of medicine, section of proctology; meeting 27 November 1974. President's address. Anorectal incontinence. Proc R Soc Med (1975) 68:881–90.
Rao SSC, Cross-Adame E, Tantiphaschika K, Attaluri A, Remes-Troche JM. Transluminal and transsacral magnetic neuro-stimulation for the assessment of neuropathy in fecal incontinence. Dis Colon Rectum (2013) (in press).
Snoeks SJ, Setchell M, Swash M, Henry MM. Injury to innervation of the anal sphincter in female rats. A quantitative morphometric study. Am J Obstet Gynecol (1974) 120:841–7. doi:10.1016/0002-9378(74)90076-9
Tettsschner T, Sorensen M, Lose G, Christiansen J. Anal and urinary incontinence in women with obstetric anal sphincter rupture. Br J Obstet Gynaecol (1996) 103:1034–40. doi:10.1111/j.1471-0528.1996.tb09557.x
Brouwer R, Duthie G. Sacral nerve neuromodulation is effective treatment for fecal incontinence in the presence of a sphincter defect, pudendal neuropathy, or previous sphincter repair. Dis Colon Rectum (2010) 53:273–8. doi:10.1007/DCR.0b013e3181e4ee22
Remes-Troche JM, Rao SSC. Neurophysiological testing in anorectal disorders. Expert Rev Gastroenterol Hepatol (2008) 2:323–35. doi:10.1586/17474124.2.3.323
Remes-Troche JM, Tantiphaschika K, Attaluri A, Remes-Troche JM. Transluminal and transsacral magnetic neuro-stimulation for the assessment of neuropathy in fecal incontinence. Dis Colon Rectum (2010) 53:273–8. doi:10.1007/DCR.0b013e3181e4ee22
Rao SS, Read NW, Davison PA, Bannister JJ, Holdsworth CD. Anorectal sensitivity and responses to rectal distention in patients with ulcerative colitis. Gastroenterology (1987) 93:1270–5.
Read NW, Abourezk Y, Read MG, Howell P, Oettlewell D, Donnelly TC. Anorectal function in elderly patients with fecal impaction. Gastroenterology (1985) 99:559–66.
Lee Update on constipation and fecal incontinence

80. Omar MI, Alexander CE. Drug treatment for faecal incontinence in adults. Cochrane Database Syst Rev (2013) 6:CD002116. doi:10.1002/14651858.CD002116.pub2

81. Bharucha AE, Fletcher JG, Camilleri M, Edge J, Carlson P, Zinsmeister AR. Effects of clonidine in women with fecal incontinence. Clin Gastroenterol Hepatol (2013). doi:10.1016/j.cgh.2013.06.035

82. Norton C, Cody JD. Biofeedback and/or sphincter exercises for the treatment of faecal incontinence in adults. Cochrane Database Syst Rev (2012) 7:CD002116. doi:10.1002/14651858.CD002116.pub2

83. Heymen S, Scarlett Y, Jones K, Ringel Y, Drossman D, Whitehead WE. Perianal injectable bulking agents as treatment for fecal incontinence: results of five-year follow-up. Dis Colon Rectum (2010) 52:1730–7. doi:10.1007/DCR.0b013e3181b55455

84. Maeda Y, Laurant S, Norton C. Perianal injectable bulking agents as treatment for faecal incontinence in adults. Cochrane Database Syst Rev (2013) 2:CD007959. doi:10.1002/14651858.CD007959.pub3

85. Graf W, Melliger A, Matzel KE, Hull T, Johansson C, Bernstein M. Efficacy of dextranomer in stabilised hyaluronic acid for treatment of faecal incontinence: a randomised, sham-controlled trial. Lancet (2011) 377:997–1003. doi:10.1016/S0140-6736(11)62297-0

86. La Torre F, de la Portilla F. Long-term efficacy of dextranomer in stabilized hyaluronic acid (NASHA/Dx) for treatment of fecal incontinence. Dis Colon Rectum (2013) 56:569–74. doi:10.1007/DCR.0b013e282a97a125

87. Paton V, Wikeleidt L, Arkwright JW, Lubowski DZ, Dinning PG. The effect of sacral nerve stimulation on distal colonic motility in patients with faecal incontinence. Br J Surg (2013) 100:959–68. doi:10.1002/bjs.9114

88. Sheldon R, Kiff ES, Clarke A, Harris ML, Hamdy S. Sacral nerve stimulation reduces rectocoeal excitability in patients with faecal incontinence. Br J Surg (2005) 92:1423–31. doi:10.1002/bjs.5111

89. Vaizerzy CJ, Kamm MA, Turner JC, Nicholls RJ, Woloszko J. Effects of short term sacral nerve stimulation on anal and rectal function in patients with anal incontinence. Gut (1999) 44:407–12. doi:10.1136/gut.44.3.407

90. Falgheru M, Tracy TH, Bast J, Halverson A, Na J. Ten-year outcome after anal sphincter repair for fecal incontinence. Dis Colon Rectum (2010) 53:1604–10. doi:10.1007/DCR.0b013e3181fed557

91. Barbasass M-L, Mantoo S, Wyatt V, Meurette G, Lehar P-A. The magnetic anal sphincter in faecal incontinence: is initial success sustained over time? Colorectal Dis (2013) 15:1499–503. doi:10.1111/col.12243

92. Wong MTC, Meurette G, Wyart V, Glemain P, Lehar P-A. The artificial bowel sphincter: a study of over 50 cases from Cleveland clinic Florida. Dis Colon Rectum (2009) 52:1550–7. doi:10.1007/DCR.0b013e3182196543

Conflict of Interest Statement: The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 01 February 2014; paper pending published: 25 February 2014; accepted: 13 March 2014; published online: 24 March 2014. Citation: Lee YY (2014) What’s new in the toolbox for constipation and fecal incontinence? Front Med (Jau). 2014; 3039; doi:10.3037/med.2014.00055. This article was submitted to Gastroenterology, a section of the journal Frontiers in Medicine. Copyright © 2014 Lee. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.